- COREDividend Growth
- Large Cap Focus
- GROWTHGilead
- Healthcare & Life Sciences
- Exponential Technologies
- BALANCEDBalanced Fund
- BONDSLimited-Term Bond
- Core Bond
Ticker
ETILX
$53.90 ▼ -0.50% 12/17/2024
Nav
$53.90 ▼ -0.50% 12/17/2024
About the Fund
- Diversified, equity mutual fund representing our “best ideas”
- Seeks long-term capital appreciation
- Historical emphases in Healthcare and IT
Annualized Returns
| 1-Year | 11.26% |
| 5-Year | 9.18% |
| 10-Year | 10.37% |
| Since Inception | 13.12% |
Morningstar
| ★★★ |
US Fund Mid-Cap Growth |
Morningstar overall star rating is as of 09/30/2024 for the Fund's Class I shares compared to 511 funds in the US Fund Mid-Cap Growth category. The overall ranking is derived from a weighted average of performance associated with its 3-year, 5-year and 10-year (where applicable) Morningstar Rating metrics. The Morningstar globe ranking is as of 08/31/2024 compared to the sustainability ratings of 1595 funds in its category. Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Fund expenses: Class I, Gross Expenses 1.18%, Net Expenses 1.18%.
-
Overview
Overview
Fund Objective
Seeks to provide long-term capital appreciation.
About the Fund
A diversified mutual fund representing our "best ideas" for long-term capital appreciation. Historical emphases in small- and mid-cap growth, Health Care and Information Technology.
Fund Distinctives
A Thematic Approach
Seeking to invest in companies best positioned to participate in long-term secular investment themes.Creating Compelling Value for Society and the Global Common Good
Focused on identifying and investing in companies capable of increasing profitability and growth by serving well the needs of customers, employees, suppliers, communities, the environment, and society broadly.Designed as a Non-Correlated Source of Return
Portfolio is constructed with goals of high internal diversification and low market correlation.
There is no guarantee that the Adviser’s approach will produce the desired results. All investments involve risk, including the possible loss of principal. Portfolio Composition is subject to change at any time, and should not be considered investment advice.
-
Performance and Risk
Trailing Returns (%) As of the quarter ending 09/30/2024
Eventide Gilead Fund As of 12/17/2024.
YTD3-month 1-year 3-year 5-year 10-year Since Inception Inception Date Class I 4.45% 4.56 11.26 -6.01 9.18 10.37 13.12 02/02/2010 Class A without load 4.20% 4.50 10.98 -6.24 8.91 10.11 13.94 10/28/2009 Class A with 5.75% load -1.79% -1.52 4.59 -8.07 7.63 9.46 13.49 10/28/2009 Class C 3.45% 4.29 10.15 -6.94 8.09 9.28 13.07 10/28/2009 Class N 4.25% 4.51 11.03 -6.20 8.96 10.15 12.61 07/08/2008 Benchmarks Bloomberg US Mid Cap Growth Index 21.04% 8.09 27.45 3.34 11.84 11.08 10.61 07/08/2008 Russell Midcap Growth Index 28.15% 6.54 29.33 2.32 11.48 11.30 11.00 07/08/2008
Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index, and unmanaged index returns do not reflect any fees, expenses, or sales charges. The volatility of an index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as a listed index. This material must be read along with the Fund's prospectus, which may be obtained at eventidefunds.com/prospectus. Performance data current to the most recent month-end may be obtained by calling 1-877-771-EVEN (3836).
Market Risk AS OF 09/30/2024
Standard Deviation Beta Alpha(%) R-Squared(%) 3-yr Inception 3-yr Inception 3-yr Inception 3-yr Inception Eventide Gilead I 21.32 19.80 0.98 1.09 -9.25 -0.16 89.52 86.35 Bloomberg US Mid Cap Growth Index 20.55 16.96 1.00 1.00 - - 100.00 100.00 Russell Midcap Growth Index 21.31 17.32 1.02 1.01 -0.87 0.03 97.13 98.06
-
Portfolio
-
Investment Team
Finny Kuruvilla, MD, PhD serves as Co-Chief Investment Officer and Senior Portfolio Manager for Eventide. He serves as the Lead Portfolio Manager for the Eventide Gilead Fund, the Eventide Healthcare & Life Sciences Fund, and the Eventide Exponential Technologies Fund. He also is a Managing Director for Eventide Ventures, as well as a Founding Member of Eventide. Dr. Kuruvilla has a background in healthcare, statistics, and investing. Concurrent with his early years at Eventide, he was a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm subsequently acquired by Blackstone. Earlier in his career, Dr. Kuruvilla was a postdoctoral research fellow at the Broad Institute of Harvard and MIT, where he led the development of a new microarray between the Broad Institute and a publicly-traded company Affymetrix. Prior to his investing career, Dr. Kuruvilla was resident, chief resident, and fellow at the Brigham and Women’s Hospital and Boston Children’s Hospital, where he cared for adult and pediatric patients suffering from a variety of hematologic, oncologic, and autoimmune disorders. Subsequently, he was a research fellow at MIT where he designed and implemented statistical algorithms involving logistic regression and pseudo-Bayesian expectation maximization. Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, an SM in Electrical Engineering and Computer Science from MIT, and a BS in Chemistry from Caltech.
-
Literature
